BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cordis Corporation (JNJ) Release: SAPPHIRE Worldwide Study Data Presented at TCT 2012


10/24/2012 9:15:53 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cordis Corporation today announced the presentation of the SAPPHIRE study results for the first 15,000 patients at the TCT 2012 conference in Miami. SAPPHIRE (STENTING AND ANGIOPLASTY WITH PROTECTION IN PATIENTS AT HIGH-RISK FOR ENDARTERECTOMY) World Wide (SWW) Registry is one of the largest carotid artery stenting (CAS) studies to date with more than 15,000 patients undergoing CAS with cerebral protection. It is a multicenter, prospective study to evaluate the outcomes of CAS using the PRECISE® Nitinol Stent and ANGIOGUARD® XP/RX Emboli Capture Guidewire System in the treatment of obstructive carotid artery disease. The peri-procedural results were presented by Christopher Metzger, MD, National Co-Principal Investigator of the study.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->